<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Well-differentiated neuroendocrine tumors of the appendix</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Well-differentiated neuroendocrine tumors of the appendix</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Well-differentiated neuroendocrine tumors of the appendix</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas E Clancy, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Ang Chan, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth K Tanabe, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 22, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Neoplasms of the appendix are rare. They are found in approximately 1 percent of appendectomy specimens [<a href="#rid1">1,2</a>] and account for only approximately 0.5 of 1 percent of intestinal neoplasms [<a href="#rid3">3</a>].</p><p>Appendiceal neoplasms comprise several histologic types:</p><p class="bulletIndent1"><span class="glyph">●</span>Epithelial neoplasms include invasive adenocarcinomas, low-grade appendiceal mucinous neoplasms, and goblet cell adenocarcinomas. Histologically, goblet cell adenocarcinomas (previously called goblet cell carcinoids or adenocarcinoids) have features of both adenocarcinomas and well-differentiated neuroendocrine tumors (NETs). They are more aggressive than well-differentiated NETs [<a href="#rid4">4</a>] and are classified and staged as appendiceal carcinomas [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/119122.html" rel="external">"Epithelial tumors of the appendix"</a> and  <a class="medical medical_review" href="/z/d/html/118407.html" rel="external">"Appendiceal mucinous lesions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neuroendocrine neoplasms of the gastrointestinal tract include well-differentiated NETs (grades 1, 2, and 3), poorly differentiated neuroendocrine carcinomas (large cell and small cell types), and mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN) [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1">MiNEN typically show a combination of neuroendocrine carcinoma and adenocarcinoma, and these tumors are treated like high-grade neuroendocrine carcinomas. (See  <a class="medical medical_review" href="/z/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms"</a>.)</p><p></p><p>This topic will focus on the clinical presentation, staging workup, and treatment of well-differentiated NETs arising in the appendix. The evaluation and management of epithelial neoplasms (including goblet cell adenocarcinomas) and mucinous lesions arising in the appendix, the management of high-grade neuroendocrine carcinomas of the digestive tract, and the pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system are all addressed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/119122.html" rel="external">"Epithelial tumors of the appendix"</a> and  <a class="medical medical_review" href="/z/d/html/118407.html" rel="external">"Appendiceal mucinous lesions"</a> and  <a class="medical medical_review" href="/z/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms"</a> and  <a class="medical medical_review" href="/z/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">TERMINOLOGY AND CLASSIFICATION</span><span class="headingEndMark"> — </span>NETs arising in the tubular gastrointestinal tract, lung, and genitourinary tract were initially referred to as "carcinoids" because they seemed morphologically different and clinically less aggressive than the more common gastrointestinal tract adenocarcinomas.</p><p>While most NETs are relatively slow-growing neoplasms, some behave aggressively. Histologic grade and differentiation correlate closely with clinical behavior. Grade refers to the proliferative activity of tumors, commonly measured by the mitotic rate (number of mitotic figures per 10 high-powered fields [HPF]) or the Ki-67 index. By contrast, differentiation refers to the extent to which neoplastic cells resemble their nonneoplastic counterparts.</p><p>The most recent nomenclature for NETs of the digestive system (which includes the appendix) from the World Health Organization (WHO) distinguishes two broad subgroups  (<a class="graphic graphic_table graphicRef122325" href="/z/d/graphic/122325.html" rel="external">table 1</a>) [<a href="#rid7">7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Well-differentiated NETs, which are further subdivided into low grade, intermediate grade, and high grade according to proliferative rate. In general, the clinical behavior of the low- and intermediate-grade tumors is relatively indolent. The clinical behavior of well-differentiated, high-grade tumors is somewhat worse than that of well-differentiated, intermediate-grade NETs, but it is better than that of poorly differentiated neuroendocrine carcinomas. (See  <a class="medical medical_review" href="/z/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms", section on 'High-grade well-differentiated tumors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Poorly differentiated neuroendocrine carcinomas, which are high-grade carcinomas that resemble small cell or large cell neuroendocrine carcinomas of the lung  (<a class="graphic graphic_picture graphicRef74630" href="/z/d/graphic/74630.html" rel="external">picture 1</a>) [<a href="#rid8">8</a>]. They generally behave in a biologically aggressive fashion.</p><p></p><p>Within the appendix, 70 to 75 percent of neuroendocrine neoplasms are well-differentiated NETs; the remainder are high-grade neuroendocrine carcinomas [<a href="#rid4">4,9</a>]. A more detailed discussion of the pathology and classification of NETs arising in the digestive tract and of high-grade neuroendocrine carcinomas arising in the digestive tract is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on 'Classification and terminology'</a> and  <a class="medical medical_review" href="/z/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms"</a>.)</p><p>In addition, a separate category, mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN), typically shows a combination of neuroendocrine carcinoma and adenocarcinoma, and these tumors are treated like high-grade neuroendocrine carcinomas [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms"</a>.)</p><p class="headingAnchor" id="H915589824"><span class="h2">Carcinoid syndrome</span><span class="headingEndMark"> — </span>As with other intestinal well-differentiated NETs, those arising in the appendix can secrete serotonin and other vasoactive substances  (<a class="graphic graphic_table graphicRef79329" href="/z/d/graphic/79329.html" rel="external">table 2</a>). These substances are responsible for carcinoid syndrome, which is characterized by episodic flushing, wheezing, diarrhea, and right-sided valvular heart disease. More than 90 percent of patients with carcinoid syndrome have metastatic disease, typically to the liver. Midgut NETs (ie, those arising in the appendix and small bowel) are more commonly associated with classic carcinoid syndrome than those that arise in the foregut or hindgut  (<a class="graphic graphic_table graphicRef56015" href="/z/d/graphic/56015.html" rel="external">table 3</a>). However, the presence of carcinoid syndrome is relatively rare in patients with appendiceal NETs compared with those with small intestinal NETs [<a href="#rid10">10-12</a>], and it is generally indicative of metastatic disease. (See  <a class="medical medical_review" href="/z/d/html/2613.html" rel="external">"Clinical characteristics of well-differentiated neuroendocrine (carcinoid) tumors arising in the gastrointestinal and genitourinary tracts"</a> and  <a class="medical medical_review" href="/z/d/html/2614.html" rel="external">"Clinical features of carcinoid syndrome"</a>.)</p><p class="headingAnchor" id="H4239029607"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Well-differentiated NETs are relatively rare tumors, but the incidence has been rising over time in the United States and elsewhere. As an example, in an analysis of 64,971 NETs reported to the Surveillance, Epidemiology, and End Results (SEER) registry, the age-adjusted incidence rate for all NETs rose from 1.09 to 6.98 per 100,000 between 1973 and 2012 [<a href="#rid13">13</a>]. The appendix accounts for between 16 and 38 percent of all NETs arising within the tubular intestinal tract; the majority arise in the small bowel [<a href="#rid14">14,15</a>]. (See  <a class="medical medical_review" href="/z/d/html/2613.html" rel="external">"Clinical characteristics of well-differentiated neuroendocrine (carcinoid) tumors arising in the gastrointestinal and genitourinary tracts", section on 'Epidemiology'</a>.)</p><p>The reported incidence of appendiceal NETs is 3 to 9 per 1000 appendectomies, accounting for approximately one NET in every 150 to 300 appendectomies [<a href="#rid16">16-18</a>]. However, the distribution of tumor types within the appendix might be changing over time:</p><p class="bulletIndent1"><span class="glyph">●</span>In some older reports, well-differentiated NETs accounted for over 50 percent of neoplasms arising in the appendix  (<a class="graphic graphic_table graphicRef69317" href="/z/d/graphic/69317.html" rel="external">table 4</a>) [<a href="#rid1">1,18</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>More recently, mucinous neoplasms seem to be more common:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a large series of appendiceal tumors derived from the SEER database of the National Cancer Institute (NCI) between 1973 and 2003, the most frequent histology was mucinous adenocarcinoma, followed by intestinal-type adenocarcinoma; NETs ("malignant carcinoids") comprised only 11 percent  (<a class="graphic graphic_table graphicRef55911" href="/z/d/graphic/55911.html" rel="external">table 5</a>) [<a href="#rid19">19</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In another large contemporary surgical series, well-differentiated NETs accounted for 18 percent of the unexpected histopathologic findings in appendectomy specimens; low-grade mucinous neoplasms and simple mucoceles (also termed "retention cysts") accounted for nearly one-half of the cases [<a href="#rid2">2</a>].</p><p></p><p>Appendiceal NETs are detected most commonly in patients in their 40s, which is much younger than the average age for other primary malignant appendiceal neoplasms [<a href="#rid16">16,20,21</a>]. Epidemiologic studies show a slight but consistently higher incidence in women, although this association has in part been attributed to the greater frequency of incidental appendectomies in women who undergo pelvic surgery. (See  <a class="medical medical_review" href="/z/d/html/2613.html" rel="external">"Clinical characteristics of well-differentiated neuroendocrine (carcinoid) tumors arising in the gastrointestinal and genitourinary tracts", section on 'Appendix'</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>The majority of appendiceal NETs are found incidentally at the time of appendectomy. Most are submucosal and located in the distal one-third of the appendix, where they are unlikely to cause obstruction  (<a class="graphic graphic_picture graphicRef50408 graphicRef80087" href="/z/d/graphic/50408.html" rel="external">picture 2A-B</a>) [<a href="#rid1">1,22</a>]. As a result, most patients are asymptomatic at presentation. Symptoms are more likely with large tumors and with metastases beyond the regional lymph nodes. Approximately 10 percent of appendiceal NETs are located at the base of the appendix, where they can cause obstruction leading to appendicitis [<a href="#rid23">23</a>].</p><p>The likelihood of regional and distant metastases at presentation is related to tumor size but is generally lower for appendiceal as compared with small intestinal NETs  (<a class="graphic graphic_table graphicRef82306" href="/z/d/graphic/82306.html" rel="external">table 6</a>). In a more recent series of 902 well-differentiated NETs derived from the National Cancer Database (NCDB) that examined the relationship between tumor size and risk of metastases, nodal metastases were present at diagnosis in 12 percent of patients with tumors ≤2 cm and in 43 percent of those with larger tumors [<a href="#rid4">4</a>]. The corresponding rates for distant metastases were 0.8 and 4.1 percent for smaller and larger tumors, respectively. Higher rates of nodal involvement in patients with tumor size 1 to 2 cm are reported by others [<a href="#rid17">17,24</a>].</p><p>Distant metastases predominantly affect the liver [<a href="#rid9">9</a>]. Extrahepatic metastases are extremely uncommon [<a href="#rid9">9,25,26</a>]. Features of carcinoid syndrome may be present in patients with tumors that have metastasized to the liver. </p><p class="headingAnchor" id="H4"><span class="h1">STAGING AND PROGNOSIS</span><span class="headingEndMark"> — </span>The 2010 American Joint Committee on Cancer (AJCC) staging manual contained a Tumor, Node, Metastasis (TNM) staging system for well-differentiated appendiceal NETs for the first time; the most recent version (eighth edition, 2017) is outlined in the table  (<a class="graphic graphic_table graphicRef111126" href="/z/d/graphic/111126.html" rel="external">table 7</a>) [<a href="#rid27">27</a>]. Notably, goblet cell adenocarcinomas and high-grade neuroendocrine carcinomas are more aggressive than well-differentiated NETs and are classified and staged according to the criteria for appendiceal carcinomas. (See  <a class="medical medical_review" href="/z/d/html/119122.html" rel="external">"Epithelial tumors of the appendix", section on 'Goblet cell adenocarcinoma'</a>.)</p><p class="headingAnchor" id="H6982135"><span class="h2">Staging workup</span><span class="headingEndMark"> — </span>A staging workup is advised for individuals with an appendiceal NET &gt;2 cm, those with an incomplete resection (either a lack of nodes or a positive margin), and those with concern for distant metastases based on clinical symptoms. As noted above, the likelihood of regional and distant metastases is related to tumor size  (<a class="graphic graphic_table graphicRef82306" href="/z/d/graphic/82306.html" rel="external">table 6</a>).</p><p>To assess possible liver involvement, consensus-based guidelines from the National Comprehensive Cancer Network (NCCN) recommend a helical, contrast-enhanced, triple-phase computed tomography (CT) scan or magnetic resonance imaging (MRI) for individuals with an appendiceal NET &gt;2 cm, those with an incomplete resection (nodes, margin), and those with concern for distant metastases [<a href="#rid28">28</a>]. Contrast-enhanced MRI is preferred by some physicians because of its greater sensitivity for liver metastases. (See  <a class="medical medical_review" href="/z/d/html/2622.html" rel="external">"Diagnosis of carcinoid syndrome and tumor localization", section on 'Magnetic resonance imaging'</a>.)</p><p>Somatostatin receptor-based diagnostic imaging (with indium-111 pentetreotide single-photon emission computed tomography [SPECT] imaging [OctreoScan] or <a class="drug drug_general" data-topicid="108440" href="/z/d/drug information/108440.html" rel="external">gallium Ga-68 DOTATATE</a> [or gallium Ga-68 DOTATOC or <a class="drug drug_general" data-topicid="129471" href="/z/d/drug information/129471.html" rel="external">copper Cu-64 DOTATATE</a>] integrated positron emission tomography [PET]/CT scanning) offers whole-body imaging and is the most sensitive imaging modality for diagnosis and staging of metastatic disease outside of the liver. Where available, PET/CT using one of the radiolabeled somatostatin analogs is preferred over OctreoScan because of greater sensitivity. (See  <a class="medical medical_review" href="/z/d/html/2622.html" rel="external">"Diagnosis of carcinoid syndrome and tumor localization", section on 'Somatostatin receptor-based imaging'</a> and  <a class="medical medical_review" href="/z/d/html/2194.html" rel="external">"Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring", section on 'Somatostatin receptor-based imaging techniques'</a>.)</p><p>However, in general, somatostatin receptor-based diagnostic imaging is not necessary for most patients [<a href="#rid12">12,29</a>]. Consistent with guidelines from the European Neuroendocrine Tumor Society (ENETS), we restrict preoperative testing to patients with higher risk disease who have an increased likelihood of spread and to those with suspected metastatic disease and/or symptoms suggestive of carcinoid syndrome [<a href="#rid12">12</a>]. (See <a class="local">'Carcinoid syndrome'</a> above and  <a class="medical medical_review" href="/z/d/html/2194.html" rel="external">"Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring"</a>.)</p><p class="headingAnchor" id="H2983181202"><span class="h2">Colonoscopy</span><span class="headingEndMark"> — </span>A colonoscopy is reasonable, as approximately 20 percent of NETs are associated with a synchronous non-NET neoplasm [<a href="#rid21">21,29</a>], 25 to 50 percent of which are colorectal cancers [<a href="#rid30">30,31</a>]. Whether this is needed in very young patients with small well-differentiated appendiceal NETs is unclear.</p><p class="headingAnchor" id="H6982325"><span class="h2">Assay of tumor markers</span><span class="headingEndMark"> — </span>Although some guidelines advocate baseline measurement of serum levels of chromogranin A (CgA) and measurement of the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA) in a 24-hour urine collection [<a href="#rid29">29</a>], we do not routinely pursue this testing.</p><p>NETs have the capacity to produce and secrete a variety of bioactive amines and peptides. Elevated urinary levels of 5-HIAA are highly specific for serotonin-producing NETs (ie, those arising in the midgut), but they are not particularly sensitive, particularly for localized tumors. Twenty-four-hour urine 5-HIAA can be assessed if there is suspicion for carcinoid syndrome in the setting of advanced disease. (See  <a class="medical medical_review" href="/z/d/html/130551.html" rel="external">"Overview of tumor biomarkers in gastroenteropancreatic neuroendocrine tumors", section on 'Serotonin and 5-hydroxyindoleacetic acid (5-HIAA)'</a>.)</p><p>Chromogranin A (CgA) is a nonhormonal protein that is stored and released with peptides and amines in NETs. Because it does not rely on serotonin secretion, serum level of CgA may be a more sensitive marker than urinary 5-HIAA for gastroenteropancreatic NETs, including those arising in the appendix; however, it is less specific [<a href="#rid32">32</a>]. Elevated CgA levels are present in a number of other conditions  (<a class="graphic graphic_table graphicRef73287" href="/z/d/graphic/73287.html" rel="external">table 8</a>), and specificity depends on the cutoff value. Despite a high volume of published studies evaluating CgA in NETs, guidelines have increasingly deemphasized the role of this biomarker in clinical care. (See  <a class="medical medical_review" href="/z/d/html/130551.html" rel="external">"Overview of tumor biomarkers in gastroenteropancreatic neuroendocrine tumors", section on 'Role of nonhormonal tumor markers in clinical practice'</a>.)</p><p class="headingAnchor" id="H6982142"><span class="h2">Prognosis</span><span class="headingEndMark"> — </span>Clinical behavior and prognosis are best predicted by tumor size. Tumors &lt;2 cm (found in approximately 95 percent of patients) are unlikely to have metastasized, while up to one-third of larger lesions are metastatic at diagnosis (but usually to regional nodes rather than the liver)  (<a class="graphic graphic_table graphicRef82306" href="/z/d/graphic/82306.html" rel="external">table 6</a>) [<a href="#rid23">23,33-35</a>]. In one series of 150 patients with appendiceal NETs from the Mayo Clinic, none of the 127 patients with tumors &lt;2 cm metastasized compared with 3 of 14 with tumors 2 to 3 cm and four of nine with tumors larger than 4 cm [<a href="#rid33">33</a>].</p><p>Outcome is stage dependent. (See <a class="local">'Staging and prognosis'</a> above.)</p><p>Prognosis was addressed in an analysis of 900 appendiceal NETs derived from the Surveillance, Epidemiology, and End Results (SEER) registry of the National Cancer Institute (NCI) [<a href="#rid36">36</a>]. Five-year appendiceal NET-specific survival rates were as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Tumor size &lt;2 cm without regional nodal or distant metastases – 100 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tumor size ≥2 but &lt;3 cm with regional nodal metastases, or tumor size ≥3 cm with or without regional nodal or distant metastases – 78 percent</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Distant metastatic spread – 32 percent</p><p></p><p class="headingAnchor" id="H821927304"><span class="h3">Impact of perforation</span><span class="headingEndMark"> — </span>Appendiceal NETs are mostly found incidentally during surgery for appendicitis; perforation of the appendix occurs in 10 to 20 percent of such cases [<a href="#rid19">19</a>]. The best available evidence (which is limited) suggests that perforation has no influence on the prognosis of classical appendiceal NETs. In a literature review that identified 103 patients with a classical appendiceal NET and associated perforation, no peritoneal recurrence or death was described [<a href="#rid37">37</a>]. Thus, the presence of a perforation need not influence the treatment or posttreatment surveillance plan.</p><p class="headingAnchor" id="H5"><span class="h1">TREATMENT OF LOCALIZED DISEASE</span></p><p class="headingAnchor" id="H2005771571"><span class="h2">Indications for hemicolectomy</span><span class="headingEndMark"> — </span>The majority of patients will be diagnosed after a simple appendectomy. We suggest completion right hemicolectomy with lymph node retrieval along the ileocolic and right colic arteries for all patients with a tumor &gt;2 cm and for smaller tumors between 1 and 2 cm in the presence of deep mesoappendiceal invasion (&gt;3 mm), positive or unclear margins, a higher proliferative rate (grade ≥2  (<a class="graphic graphic_table graphicRef122325" href="/z/d/graphic/122325.html" rel="external">table 1</a>)), lymphovascular invasion, and mixed histology (goblet cell adenocarcinoma). For well-differentiated NETs less than 1 cm in size, and for those tumors between 1.0 and 1.9 cm in the absence of mesoappendiceal invasion, positive/unclear margins, a higher proliferative rate, angioinvasion, or mixed histology, simple appendectomy alone is adequate. </p><p>These recommendations are consistent with consensus-based guidelines from the North American Neuroendocrine Tumor Society (NANETS) and the European Neuroendocrine Tumor Society (ENETS) [<a href="#rid12">12,38,39</a>]. However, this is a controversial area, and others disagree, considering appendectomy alone to be adequate for all tumors &lt;2 cm, even with mesoappendiceal invasion or other adverse histologic features [<a href="#rid33">33,40,41</a>]. A summary of recommendations from different expert groups for management of appendiceal neuroendocrine neoplasms according to size and other features is presented in the table  (<a class="graphic graphic_table graphicRef121675" href="/z/d/graphic/121675.html" rel="external">table 9</a>). Links to additional society guidelines can be found elsewhere. (See <a class="local">'Society guideline links'</a> below.)</p><p>The optimal surgical management for appendiceal NETs is subject to some debate. Because most are discovered incidentally in an appendectomy specimen done for other reasons, a decision must be made whether or not to return the patient to the operating room for a right hemicolectomy. Unlike simple appendectomy, colectomy removes the draining lymph nodes of the appendix and any residual disease that might remain at the base of the appendix or in the mesoappendix.</p><p>Data from the large Mayo Clinic series cited above suggest that tumor size is an important determinant of the need for further surgery [<a href="#rid33">33</a>]. None of the 120 patients with tumors less than 2 cm developed disease recurrence after simple appendectomy compared with 1 of 12 with a larger tumor. Furthermore, in a compilation of reports from single centers and large population and literature surveys, the risk of nodal metastases at diagnosis was 0, 7.5, and 33 percent for patients with appendiceal NETs &lt;1, 1 to 1.9, and &gt;2 cm, respectively  (<a class="graphic graphic_table graphicRef82306" href="/z/d/graphic/82306.html" rel="external">table 6</a>) [<a href="#rid35">35</a>].</p><p>In addition to tumor size, other studies suggest that lymphovascular and perineural invasion are also risk factors for nodal metastases [<a href="#rid24">24,42</a>].</p><p>These data, taken together with the fact that as many as 88 percent of those with regional nodal metastases survive for five years or longer, support the view that patients with tumors &gt;2 cm in size should undergo right colectomy.</p><p>On the other hand, whether or not a colectomy should be performed in some patients with smaller (&lt;2 cm) tumors is unclear; the available data are conflicting:</p><p class="bulletIndent1"><span class="glyph">●</span>Although the Mayo Clinic series suggested that appendectomy is sufficient in such cases [<a href="#rid33">33</a>], at least two older reports demonstrate a higher potential for metastatic spread with small tumors in the setting of mesoappendiceal invasion [<a href="#rid43">43,44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A review of the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute (NCI) reported much higher rates of lymph node metastases than previously appreciated for tumors &lt;2 cm [<a href="#rid17">17</a>]. Among patients reported to the database between 1988 and 2003, lymph node metastases were found in 15 percent (4 of 27) of patients with appendiceal NETs less than 1 cm and in 47 percent (16 of 34) of those with NETs between 1.0 and 1.9 cm. The 10-year survival rates in these two groups were 100 and 92 percent, respectively, while it was 91 percent in patients with NETs &gt;2 cm, despite the fact that 86 percent of them had lymph node metastases. Whether these excellent outcomes reflected favorable biology or the impact of surgical removal of nodal metastases is unclear.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A second SEER-based series of 573 patients with well-differentiated appendiceal NETs reported to the registry between 1988 and 2013 reported a 31 percent probability of nodal metastases in tumors 1.1 to 2 cm and a 64 percent probability in tumors &gt;2 cm [<a href="#rid45">45</a>]. The analysis also indicated the prognostic importance of the number of nodes evaluated; among those with tumors &gt;1 cm, five-year overall survival rates were worse when 12 or fewer lymph nodes were identified (five-year survival 88 versus 96 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>On the other hand, benefit for completion right hemicolectomy could not be shown in a series from the National Cancer Database (NCDB) specifically addressing management of 1 to 2 cm appendiceal NETs [<a href="#rid40">40</a>]. Of the 916 patients reported to the database between 1998 and 2011 who had appendiceal NETs between 1 and 2 cm, 42 percent were managed with primary resection, and 58 percent were managed with a right hemicolectomy. Formal resection of the right colon did not appear to improve survival (five-year survival 88.7 versus 87.4 percent), even for higher grade and higher stage tumors. Among those undergoing a right hemicolectomy, 28 percent had positive nodes. Other observational studies have demonstrated similar results [<a href="#rid41">41</a>]. </p><p></p><p>A nomogram has been developed to predict the risk of nodal metastases based on tumor size and depth of invasion; however, there is no agreement as to what level of risk would warrant a right hemicolectomy [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H393097112"><span class="h2">Evaluating for synchronous colorectal cancers</span><span class="headingEndMark"> — </span>If a right hemicolectomy is pursued, prior to the procedure, a full colonoscopy could be undertaken to rule out a synchronous colon cancer. However, whether this is needed in a young person with a small well-differentiated appendiceal NET is unclear.</p><p>The surgeon should also perform a complete inspection of the bowel intraoperatively since up to 25 percent of midgut NETs (small bowel, proximal colon) may be multifocal and are sometimes associated with malignant gastrointestinal tumors of other histologic types [<a href="#rid47">47,48</a>].</p><p class="headingAnchor" id="H6"><span class="h1">POSTTREATMENT FOLLOW-UP</span><span class="headingEndMark"> — </span>There are no randomized trial data or evidence-based guidelines for follow-up after resection of a gastrointestinal NET at any site. Recommendations are generally based on risk and anticipated patterns of recurrence based on the primary tumor characteristics. Various organizations have put forth recommendations for follow-up surveillance after resection:</p><p class="bulletIndent1"><span class="glyph">●</span>The consensus-based recommendations from the National Comprehensive Cancer Network (NCCN) are based on tumor size [<a href="#rid28">28</a>]. Patients with tumors &lt;2 cm do not require routine surveillance, and tests should only be ordered as clinically indicated. For tumors &gt;2 cm, a history and physical examination and abdominal/pelvic imaging are recommended between 3 and 12 months after resection, and consideration of tumor markers (5-hydroxyindoleacetic acid [5-HIAA], chromogranin) as clinically indicated; after the first year, a history and physical examination and abdominal/pelvic imaging are recommended every 12 to 24 months. Beyond 10 years, surveillance is recommended as clinically indicated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The North American Neuroendocrine Tumor Society (NANETS) has similar recommendations to the NCCN, with the exception that tumors &lt;1 cm do not generally require further surveillance, but tumors between 1 and 2 cm with poor prognostic features (nodal metastases, lymphovascular invasion, mesoappendiceal invasion, intermediate- or high-grade or mixed histology) should trigger surveillance similar to that for tumors &gt;2 cm, with a history and physical examination, consideration of tumor markers (5-HIAA and chromogranin), and consideration of CT or MRI within three to six months of surgery and subsequently every 6 to 12 months for at least seven years after surgery [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The European Neuroendocrine Tumor Society (ENETS) recommends no specific follow-up strategy in cases of curative resection for appendiceal neuroendocrine neoplasms &lt;1 and for those tumors &gt;1 cm that are treated with right hemicolectomy without proof of lymph node involvement [<a href="#rid12">12</a>]. Long-term follow-up is recommended in cases with involvement of lymph nodes or resected distant metastases. Regular follow-up is also advised for patients who have not undergone hemicolectomy and have tumors &gt;1 cm with risk factors (including location at the base of the appendix, deep mesoappendiceal invasion, intermediate-grade histology, and vascular invasion).</p><p></p><p>In our practice, we generally recommend the following:</p><p class="bulletIndent1"><span class="glyph">●</span>For appendiceal NETs ≤2 cm without high-risk features (nodal metastases, lymphovascular invasion, mesoappendiceal invasion, intermediate- or high-grade or mixed histology) that are confined to the appendix and treated with simple appendectomy, we do not recommend routine follow-up.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For larger or node-positive tumors treated with right hemicolectomy, between 3 and 12 months postresection, we perform a history and physical examination and perform CT or MRI imaging. The value of tumor markers, including chromogranin A, to aid in early detection of recurrence has not been established, and we do not routinely obtain these biomarkers for surveillance.</p><p></p><p class="bulletIndent1">Beyond one year postresection, we perform a history and physical examination every 6 to 12 months and cross-sectional imaging studies annually. We do not generally include somatostatin receptor-based imaging in the posttreatment follow-up strategy, but this could be considered as a baseline assessment in a patient with high-risk features if it was not done preoperatively [<a href="#rid49">49</a>].</p><p></p><p>The optimal duration of follow-up is not established. Most guidelines, including those of the NCCN and NANETS [<a href="#rid28">28,50</a>], suggest 10 years of follow-up.</p><p class="headingAnchor" id="H7"><span class="h1">TREATMENT OF METASTATIC DISEASE</span><span class="headingEndMark"> — </span>For patients who have somatostatin receptor-positive disease (as determined by somatostatin receptor-based diagnostic imaging), symptoms of carcinoid syndrome can often be well controlled with long-acting somatostatin analogs. Although few patients have objective tumor regression, somatostatin analogs prolong the time to disease progression and overall survival in asymptomatic patients. (See  <a class="medical medical_review" href="/z/d/html/16901.html" rel="external">"Metastatic well-differentiated gastrointestinal neuroendocrine (carcinoid) tumors: Systemic therapy options to control tumor growth", section on 'Somatostatin analogs'</a>.)</p><p>Liver resection for selected patients may be beneficial, particularly for symptom relief. If liver resection is not feasible, then hepatic artery embolization can be considered. (See  <a class="medical medical_review" href="/z/d/html/16105.html" rel="external">"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion", section on 'Surgical resection'</a> and  <a class="medical medical_review" href="/z/d/html/16105.html" rel="external">"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion", section on 'Hepatic arterial embolization'</a>.)</p><p>The best systemic therapy option for patients with progressive metastatic gastrointestinal NETs that are not amenable to local ablative therapies or resection is not established.</p><p>For patients with somatostatin receptor-positive tumors (as determined by somatostatin receptor-based diagnostic imaging), treatment with peptide receptor radioligand therapy (PRRT) using radiolabeled somatostatin analogs (eg, <a class="drug drug_general" data-topicid="116519" href="/z/d/drug information/116519.html" rel="external">lutetium Lu-177 dotatate</a> [<sup>177</sup>Lu-Dotatate]) is an option. <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">Everolimus</a> can also be considered for patients with progression following somatostatin analog therapy who are not candidates for PRRT. (See  <a class="medical medical_review" href="/z/d/html/16901.html" rel="external">"Metastatic well-differentiated gastrointestinal neuroendocrine (carcinoid) tumors: Systemic therapy options to control tumor growth", section on 'Radiolabeled somatostatin analogs'</a> and  <a class="medical medical_review" href="/z/d/html/16901.html" rel="external">"Metastatic well-differentiated gastrointestinal neuroendocrine (carcinoid) tumors: Systemic therapy options to control tumor growth", section on 'Everolimus'</a>.)</p><p>The role of cytotoxic chemotherapy for midgut NET continues to be debated. The management of metastatic gastrointestinal NETs is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16901.html" rel="external">"Metastatic well-differentiated gastrointestinal neuroendocrine (carcinoid) tumors: Systemic therapy options to control tumor growth"</a>.)</p><p class="headingAnchor" id="H1760552482"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111962.html" rel="external">"Society guideline links: Well-differentiated gastroenteropancreatic neuroendocrine tumors"</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Terminology and classification</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neoplasms arising in the appendix are divided into epithelial neoplasms (which include invasive adenocarcinomas, low-grade appendiceal mucinous neoplasms, and goblet cell adenocarcinomas) and neuroendocrine neoplasms (which include well-differentiated neuroendocrine tumors [NETs], neuroendocrine carcinomas [large cell and small cell types], and mixed neuroendocrine-non-neuroendocrine neoplasms [MiNEN]). MiNEN typically show a combination of neuroendocrine carcinoma and adenocarcinoma, and these tumors are treated like high-grade neuroendocrine carcinomas.</p><p></p><p class="bulletIndent2">Among neuroendocrine neoplasms, histologic grade and differentiation correlate closely with clinical behavior  (<a class="graphic graphic_table graphicRef122325" href="/z/d/graphic/122325.html" rel="external">table 1</a>). The majority (70 to 75 percent) of neuroendocrine neoplasms arising in the appendix are well-differentiated, grade 1 or 2 NETs. (See <a class="local">'Terminology and classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology and clinical presentation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The majority of appendiceal NETs are asymptomatic and found incidentally at the time of appendectomy. The reported incidence of appendiceal NETs is 3 to 9 per 1000 appendectomies, accounting for approximately one NET in every 150 to 300 appendectomies. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>NETs arising in the appendix can secrete serotonin and other vasoactive substances, which cause carcinoid syndrome, characterized by episodic flushing, wheezing, and diarrhea. Carcinoid syndrome is relatively rare in patients with appendiceal NETs, and it generally indicates the presence of metastatic disease, typically to the liver. (See <a class="local">'Carcinoid syndrome'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Staging and prognosis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A preoperative staging workup is advised for individuals with tumor size &gt;2 cm, those with an incomplete resection at the time of simple appendectomy (either a lack of nodes or a positive margin), and those with concern for distant metastases based on clinical symptoms. To assess for liver involvement, the staging workup should include a helical, contrast-enhanced, triple-phase CT scan or MRI. Contrast-enhanced MRI is preferred by some physicians because of its greater sensitivity for liver metastases. (See <a class="local">'Staging workup'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Somatostatin receptor-based diagnostic imaging is not necessary for most patients. We obtain testing in the preoperative situation for individuals with higher-risk disease and for those with suspected metastatic disease or symptoms suggestive of carcinoid syndrome.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of localized disease and prognosis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For well-differentiated NETs discovered at the time of simple appendectomy, we suggest reoperation with a right hemicolectomy with lymph node retrieval along the ileocolic and right colic arteries for tumors larger than 2 cm, and for tumors between 1 and 1.9 cm with deep mesoappendiceal (&gt;3 mm) or lymphovascular invasion, positive or uncertain margins, or mixed histology (eg, goblet cell adenocarcinoma) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2">Simple appendectomy alone is sufficient for tumors &lt;1.0 cm in the absence of mesoappendiceal invasion, and for tumors 1 to 1.9 cm that lack mesoappendiceal invasion and other adverse histologic features. (See <a class="local">'Terminology and classification'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Most patients have localized disease, and the prognosis is excellent. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Following treatment, we follow the National Comprehensive Cancer Network (NCCN) guidelines for posttreatment surveillance (see <a class="local">'Posttreatment follow-up'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For appendiceal NETs ≤2 cm confined to the appendix and treated with simple appendectomy, no follow-up is required.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For larger or node-positive tumors treated with right hemicolectomy, between 3 and 12 months postresection, we perform a history and physical examination and CT imaging of the abdomen/pelvis. Tumor markers, including chromogranin A, are not routinely obtained because their value in early detection of recurrence has not been established.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Between 1 to 10 years post resection, we perform a history and physical examination and radiographic imaging studies every one to two years.</p><p></p><p class="headingAnchor" id="H2935149388"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Jeffrey A Meyerhardt, MD, MPH, and Richard Swanson, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Connor SJ, Hanna GB, Frizelle FA. Appendiceal tumors: retrospective clinicopathologic analysis of appendiceal tumors from 7,970 appendectomies. Dis Colon Rectum 1998; 41:75.</a></li><li><a class="nounderline abstract_t">Unver N, Coban G, Arıcı DS, et al. Unusual Histopathological Findings in Appendectomy Specimens: A Retrospective Analysis of 2047 Cases. Int J Surg Pathol 2019; 27:142.</a></li><li><a class="nounderline abstract_t">HESKETH KT. The management of primary adenocarcinoma of the vermiform appendix. Gut 1963; 4:158.</a></li><li><a class="nounderline abstract_t">Hsu C, Rashid A, Xing Y, et al. Varying malignant potential of appendiceal neuroendocrine tumors: importance of histologic subtype. J Surg Oncol 2013; 107:136.</a></li><li class="breakAll">Misdraji J, Carr NJ, Pai RK. Appendiceal goblet cell adenocarcinoma. In: WHO Classification of Tumours: Digestive System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, Lyon 2019. p.149.</li><li class="breakAll">Couvelard A, Perren A, Sipos B. Appendiceal neuroendocrine neoplasms. In: WHO Classification of Tumours: Digestive System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, Lyon 2019. p.152.</li><li class="breakAll">Klimstra DS, Kloppell G, La Rosa S, Rindi G. Classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours: Digestive System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, Lyon 2019. p.16.</li><li><a class="nounderline abstract_t">Gustafsson BI, Kidd M, Chan A, et al. Bronchopulmonary neuroendocrine tumors. Cancer 2008; 113:5.</a></li><li><a class="nounderline abstract_t">Cai W, Tan Y, Ge W, et al. Pattern and risk factors for distant metastases in gastrointestinal neuroendocrine neoplasms: a population-based study. Cancer Med 2018; 7:2699.</a></li><li><a class="nounderline abstract_t">Galanopoulos M, Toumpanakis C. The Problem of Appendiceal Carcinoids. Endocrinol Metab Clin North Am 2018; 47:661.</a></li><li><a class="nounderline abstract_t">Stinner B, Rothmund M. Neuroendocrine tumours (carcinoids) of the appendix. Best Pract Res Clin Gastroenterol 2005; 19:729.</a></li><li><a class="nounderline abstract_t">Pape UF, Niederle B, Costa F, et al. ENETS Consensus Guidelines for Neuroendocrine Neoplasms of the Appendix (Excluding Goblet Cell Carcinomas). Neuroendocrinology 2016; 103:144.</a></li><li><a class="nounderline abstract_t">Dasari A, Shen C, Halperin D, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol 2017; 3:1335.</a></li><li><a class="nounderline abstract_t">Maggard MA, O'Connell JB, Ko CY. Updated population-based review of carcinoid tumors. Ann Surg 2004; 240:117.</a></li><li><a class="nounderline abstract_t">Ellis L, Shale MJ, Coleman MP. Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. Am J Gastroenterol 2010; 105:2563.</a></li><li><a class="nounderline abstract_t">Sandor A, Modlin IM. A retrospective analysis of 1570 appendiceal carcinoids. Am J Gastroenterol 1998; 93:422.</a></li><li><a class="nounderline abstract_t">Mullen JT, Savarese DM. Carcinoid tumors of the appendix: a population-based study. J Surg Oncol 2011; 104:41.</a></li><li><a class="nounderline abstract_t">Goede AC, Caplin ME, Winslet MC. Carcinoid tumour of the appendix. Br J Surg 2003; 90:1317.</a></li><li><a class="nounderline abstract_t">Turaga KK, Pappas SG, Gamblin T. Importance of histologic subtype in the staging of appendiceal tumors. Ann Surg Oncol 2012; 19:1379.</a></li><li><a class="nounderline abstract_t">McCusker ME, Coté TR, Clegg LX, Sobin LH. Primary malignant neoplasms of the appendix: a population-based study from the surveillance, epidemiology and end-results program, 1973-1998. Cancer 2002; 94:3307.</a></li><li><a class="nounderline abstract_t">Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97:934.</a></li><li><a class="nounderline abstract_t">Roggo A, Wood WC, Ottinger LW. Carcinoid tumors of the appendix. Ann Surg 1993; 217:385.</a></li><li><a class="nounderline abstract_t">Moertel CG, Dockerty MB, Judd ES. Carcinoid tumors of the vermiform appendix. Cancer 1968; 21:270.</a></li><li><a class="nounderline abstract_t">Rault-Petit B, Do Cao C, Guyétant S, et al. Current Management and Predictive Factors of Lymph Node Metastasis of Appendix Neuroendocrine Tumors: A National Study from the French Group of Endocrine Tumors (GTE). Ann Surg 2019; 270:165.</a></li><li><a class="nounderline abstract_t">Madani A, Thomassen I, van Gestel YRBM, et al. Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Incidence, Risk Factors and Prognosis. Ann Surg Oncol 2017; 24:2199.</a></li><li><a class="nounderline abstract_t">Alexandraki KI, Kaltsas GA, Grozinsky-Glasberg S, et al. Appendiceal neuroendocrine neoplasms: diagnosis and management. Endocr Relat Cancer 2016; 23:R27.</a></li><li class="breakAll">Woltering EA, Bergsland EK, Beyer DT, et al. Neuroendocrine tumors of the appendix. In: AJCC Cancer Staging Manual, 8th ed, Amin MB (Ed), AJCC, Chicago 2017. p.389. Corrected at 4th printing, 2018.</li><li class="breakAll">National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (Accessed on July 25, 2023).</li><li><a class="nounderline abstract_t">Glasgow SC, Gaertner W, Stewart D, et al. The American Society of Colon and Rectal Surgeons, Clinical Practice Guidelines for the Management of Appendiceal Neoplasms. Dis Colon Rectum 2019; 62:1425.</a></li><li><a class="nounderline abstract_t">Saha S, Hoda S, Godfrey R, et al. Carcinoid tumors of the gastrointestinal tract: a 44-year experience. South Med J 1989; 82:1501.</a></li><li><a class="nounderline abstract_t">Marshall JB, Bodnarchuk G. Carcinoid tumors of the gut. Our experience over three decades and review of the literature. J Clin Gastroenterol 1993; 16:123.</a></li><li><a class="nounderline abstract_t">Modlin IM, Gustafsson BI, Moss SF, et al. Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 2010; 17:2427.</a></li><li><a class="nounderline abstract_t">Moertel CG, Weiland LH, Nagorney DM, Dockerty MB. Carcinoid tumor of the appendix: treatment and prognosis. N Engl J Med 1987; 317:1699.</a></li><li><a class="nounderline abstract_t">Anderson JR, Wilson BG. Carcinoid tumours of the appendix. Br J Surg 1985; 72:545.</a></li><li><a class="nounderline abstract_t">Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol 2005; 89:151.</a></li><li><a class="nounderline abstract_t">Landry CS, Woodall C, Scoggins CR, et al. Analysis of 900 appendiceal carcinoid tumors for a proposed predictive staging system. Arch Surg 2008; 143:664.</a></li><li><a class="nounderline abstract_t">Madani A, van der Bilt JD, Consten EC, et al. Perforation in appendiceal well-differentiated carcinoid and goblet cell tumors: impact on prognosis? A systematic review. Ann Surg Oncol 2015; 22:959.</a></li><li><a class="nounderline abstract_t">Boudreaux JP, Klimstra DS, Hassan MM, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas 2010; 39:753.</a></li><li><a class="nounderline abstract_t">Kunz PL, Reidy-Lagunes D, Anthony LB, et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas 2013; 42:557.</a></li><li><a class="nounderline abstract_t">Nussbaum DP, Speicher PJ, Gulack BC, et al. Management of 1- to 2-cm Carcinoid Tumors of the Appendix: Using the National Cancer Data Base to Address Controversies in General Surgery. J Am Coll Surg 2015; 220:894.</a></li><li><a class="nounderline abstract_t">Nesti C, Bräutigam K, Benavent M, et al. Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1-2 cm in size: a retrospective, Europe-wide, pooled cohort study. Lancet Oncol 2023; 24:187.</a></li><li><a class="nounderline abstract_t">Brighi N, La Rosa S, Rossi G, et al. Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study. Ann Surg 2020; 271:527.</a></li><li><a class="nounderline abstract_t">Ponka JL. Carcinoid tumors of the appendix. Report of thirty-five cases. Am J Surg 1973; 126:77.</a></li><li><a class="nounderline abstract_t">Syracuse DC, Perzin KH, Price JB, et al. Carcinoid tumors of the appendix. Mesoappendiceal extension and nodal metastases. Ann Surg 1979; 190:58.</a></li><li><a class="nounderline abstract_t">Raoof M, Dumitra S, O'Leary MP, et al. Mesenteric Lymphadenectomy in Well-Differentiated Appendiceal Neuroendocrine Tumors. Dis Colon Rectum 2017; 60:674.</a></li><li><a class="nounderline abstract_t">Mosquera C, Fitzgerald TL, Vora H, Grzybowski M. Novel nomogram combining depth of invasion and size can accurately predict the risk for regional nodal metastases for appendiceal neuroendocrine tumors (A-NET). J Surg Oncol 2017; 116:651.</a></li><li><a class="nounderline abstract_t">MOERTEL CG, SAUER WG, DOCKERTY MB, BAGGENSTOSS AH. Life history of the carcinoid tumor of the small intestine. Cancer 1961; 14:901.</a></li><li><a class="nounderline abstract_t">Kuiper DH, Gracie WA Jr, Pollard HM. Twenty years of gastrointestinal carcinoids. Cancer 1970; 25:1424.</a></li><li><a class="nounderline abstract_t">Hope TA, Bergsland EK, Bozkurt MF, et al. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. J Nucl Med 2018; 59:66.</a></li><li><a class="nounderline abstract_t">Strosberg JR, Halfdanarson TR, Bellizzi AM, et al. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. Pancreas 2017; 46:707.</a></li></ol></div><div id="topicVersionRevision">Topic 2527 Version 58.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9510314" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Appendiceal tumors: retrospective clinicopathologic analysis of appendiceal tumors from 7,970 appendectomies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30021480" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Unusual Histopathological Findings in Appendectomy Specimens: A Retrospective Analysis of 2047 Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13954206" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The management of primary adenocarcinoma of the vermiform appendix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22767417" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Varying malignant potential of appendiceal neuroendocrine tumors: importance of histologic subtype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22767417" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Varying malignant potential of appendiceal neuroendocrine tumors: importance of histologic subtype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22767417" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Varying malignant potential of appendiceal neuroendocrine tumors: importance of histologic subtype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22767417" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Varying malignant potential of appendiceal neuroendocrine tumors: importance of histologic subtype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18473355" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Bronchopulmonary neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29733523" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Pattern and risk factors for distant metastases in gastrointestinal neuroendocrine neoplasms: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30098722" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The Problem of Appendiceal Carcinoids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16253897" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Neuroendocrine tumours (carcinoids) of the appendix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26730583" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : ENETS Consensus Guidelines for Neuroendocrine Neoplasms of the Appendix (Excluding Goblet Cell Carcinomas).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28448665" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15213627" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Updated population-based review of carcinoid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20823835" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9517651" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A retrospective analysis of 1570 appendiceal carcinoids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21294132" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Carcinoid tumors of the appendix: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14598408" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Carcinoid tumour of the appendix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22302267" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Importance of histologic subtype in the staging of appendiceal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12115365" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Primary malignant neoplasms of the appendix: a population-based study from the surveillance, epidemiology and end-results program, 1973-1998.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12569593" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A 5-decade analysis of 13,715 carcinoid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8466309" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Carcinoid tumors of the appendix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4952505" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Carcinoid tumors of the vermiform appendix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29557879" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Current Management and Predictive Factors of Lymph Node Metastasis of Appendix Neuroendocrine Tumors: A National Study from the French Group of Endocrine Tumors (GTE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28204963" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Incidence, Risk Factors and Prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26483424" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Appendiceal neuroendocrine neoplasms: diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26483424" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Appendiceal neuroendocrine neoplasms: diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26483424" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Appendiceal neuroendocrine neoplasms: diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31725580" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The American Society of Colon and Rectal Surgeons, Clinical Practice Guidelines for the Management of Appendiceal Neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2595419" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Carcinoid tumors of the gastrointestinal tract: a 44-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8463615" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Carcinoid tumors of the gut. Our experience over three decades and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20217257" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3696178" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Carcinoid tumor of the appendix: treatment and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4016537" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Carcinoid tumours of the appendix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15719376" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18645109" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Analysis of 900 appendiceal carcinoid tumors for a proposed predictive staging system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25190118" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Perforation in appendiceal well-differentiated carcinoid and goblet cell tumors: impact on prognosis? A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20664473" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23591432" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Consensus guidelines for the management and treatment of neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25840530" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Management of 1- to 2-cm Carcinoid Tumors of the Appendix: Using the National Cancer Data Base to Address Controversies in General Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36640790" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1-2 cm in size: a retrospective, Europe-wide, pooled cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29995678" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4714781" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Carcinoid tumors of the appendix. Report of thirty-five cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/464679" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Carcinoid tumors of the appendix. Mesoappendiceal extension and nodal metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28594716" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Mesenteric Lymphadenectomy in Well-Differentiated Appendiceal Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28608390" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Novel nomogram combining depth of invasion and size can accurately predict the risk for regional nodal metastases for appendiceal neuroendocrine tumors (A-NET).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13771655" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Life history of the carcinoid tumor of the small intestine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5422917" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Twenty years of gastrointestinal carcinoids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29025982" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28609356" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
